<DOC>
<DOCNO>
EP-0017169
</DOCNO>
<TEXT>
<DATE>
19801015
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/095 A61K-31/165 A61K-31/405 C07D-209/28 C07C-57/00 A61K-31/42 C07C-59/00 A61K-20060101S A61K-31/44 C07C-59/64 A61K-31/235 C07C-65/05 A61K-31/40 C07C-20060101S A61P-25/04 C07C-57/58 A61K-31/19 A61K-31/403 A61P-25/00 A61K-31/185 A61K-31/105 A61K-31/61 C07D-209/00 C07C-65/00 A61K-31/615 A61K-31/21 A61P-29/00 <main>A61K-31/62</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
improved anti-inflammatory combinations having reduced ulcerogenicity.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc.<sep>
</APPLICANT>
<INVENTOR>
shen tsung-ying<sep>shen, tsung-ying<sep>shen, tsung-ying935 minisink waywestfield, new jersey 07090us<sep>shen, tsung-ying<sep>shen, tsung-ying935 minisink waywestfield, new jersey 07090us<sep>
</INVENTOR>
<ABSTRACT>
a novel drug combination for more effective treatment  of pain, fever, and inflammation with reduced ulcerogenicity  comprising either 1-(p-chlorobenzoyl)-5-methoxy-2-­ methylindole-3-acetic acid (indomethacin), and (b) a member  selected from phenyl benzoic acid compounds, especially  2-hydroxy-5-(2′,4′-difluorophenyl)benzoic acid (diflunisal),  wherein the molar ratio of (b) to (a) is from 0. 5 to 1. 0 to 15. 0  to 1. 0; or a member selected from (b) and one or more  members selected from ibuprofen, ketoprofen, naproxen,  diclofenac sodium, tolmetin, flurbiprofen, indoprofen, be­ nozaprofen, piroxicam.  
</ABSTRACT>
</TEXT>
</DOC>
